MY138975A - Novel preparation and administration form comprising an acid-labile active compound - Google Patents

Novel preparation and administration form comprising an acid-labile active compound

Info

Publication number
MY138975A
MY138975A MYPI20002403A MYPI20002403A MY138975A MY 138975 A MY138975 A MY 138975A MY PI20002403 A MYPI20002403 A MY PI20002403A MY PI20002403 A MYPI20002403 A MY PI20002403A MY 138975 A MY138975 A MY 138975A
Authority
MY
Malaysia
Prior art keywords
active compound
acid
administration form
mixture
labile active
Prior art date
Application number
MYPI20002403A
Inventor
Rango Dr Dietrich
Rudolf Dr Linder
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY138975(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of MY138975A publication Critical patent/MY138975A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

NOVEL ADMINISTRATION FORMS AND PREPARATIONS FOR ACID-LABILE ACTIVE COMPOUNDS ARE DESCRIBED. THE NOVEL ADMINISTRATION FORMS CONTAIN INDIVIDUAL ACTIVE COMPOUND UNITS, THE ACTIVE COMPOUND BEING PRESENT IN THE ACTIVE COMPOUND UNITS IN A MATRIX MADE OF A MIXTURE COMPRISING AT LEAST ONE FATTY ALCOHOL AND AT LEAST ONE SOLID PARAFIN, IN A MATRIX MADE OF A MIXTURE OF A TRIGLYCERIDE AND AT LEAST ONE SOLID PARAFFIN OR IN A MATRIX MADE OF A MIXTURE COMPRISING AT LEAST ONE FATTY ACID ESTER AND AT LEAST ONE SOLID PARAFFIN. IN PARTICULAR, THE ACTIVE COMPOUND UNITS ARE MICROSPHERES WHICH CAN BE PRODUCED BY PRILLING.
MYPI20002403A 1999-06-07 2000-05-30 Novel preparation and administration form comprising an acid-labile active compound MY138975A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19925710A DE19925710C2 (en) 1999-06-07 1999-06-07 New preparation and dosage form containing an acid labile proton pump inhibitor

Publications (1)

Publication Number Publication Date
MY138975A true MY138975A (en) 2009-08-28

Family

ID=7910295

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20002403A MY138975A (en) 1999-06-07 2000-05-30 Novel preparation and administration form comprising an acid-labile active compound

Country Status (6)

Country Link
AR (1) AR024310A1 (en)
CO (1) CO5160296A1 (en)
DE (1) DE19925710C2 (en)
MY (1) MY138975A (en)
PE (1) PE20010303A1 (en)
TW (1) TWI255720B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (en) * 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
DE10061137B4 (en) * 2000-12-07 2016-10-06 Takeda Gmbh New pharmaceutical preparation
DE10061136C1 (en) * 2000-12-07 2002-10-24 Byk Gulden Lomberg Chem Fab Stable, rapidly disintegrating tablets containing proton pump inhibitors, useful for treating elevated gastric secretion, comprising multiple drug units and auxiliaries including basic filler
CN100536844C (en) * 2000-12-07 2009-09-09 尼科梅德有限责任公司 Pharmaceutical paste comprising acid-labile activeingredient
KR20030072555A (en) * 2000-12-07 2003-09-15 알타나 파마 아게 Rapidly disintegrating tablet comprising an acid-labile active ingredient
DE10061138C1 (en) * 2000-12-07 2002-08-14 Byk Gulden Lomberg Chem Fab Pharmaceutical preparation in the form of a juice containing an acid-labile active ingredient
DE10061135C1 (en) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Stable gel preparation for oral administration of acid-labile drug, especially proton pump inhibitor, comprises multiple drug units dispersed in gel base
KR20030059318A (en) * 2000-12-07 2003-07-07 알타나 파마 아게 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
SE0101379D0 (en) 2001-04-18 2001-04-18 Diabact Ab Composition that inhibits gastric acid secretion
CA2461616A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2004004690A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
DE10244129B4 (en) * 2002-09-23 2006-04-20 Iongate Biosciences Gmbh H + -K + -ATPase assay
SE0203065D0 (en) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
PT1606261E (en) 2003-03-10 2010-01-11 Nycomed Gmbh Novel process for the preparation of roflumilast
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725924C3 (en) * 1977-06-08 1980-11-06 Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau Process for the production of spherical particles from low-melting organic substances
DE3524572A1 (en) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K SOLID PHARMACEUTICAL FORMS FOR PERORAL USE CONTAINING 9-DEOXO-11-DEOXY-9,11- (IMINO (2- (2-METHOXYETHOXY) ETHYLIDEN) -OXY) - (9S) -ERYTHROMYCIN AND METHOD FOR THE PRODUCTION THEREOF
JP2681373B2 (en) * 1988-07-18 1997-11-26 塩野義製薬株式会社 Method for manufacturing sustained-release preparation

Also Published As

Publication number Publication date
DE19925710C2 (en) 2002-10-10
DE19925710A1 (en) 2000-12-14
CO5160296A1 (en) 2002-05-30
TWI255720B (en) 2006-06-01
AR024310A1 (en) 2002-09-25
PE20010303A1 (en) 2001-03-09

Similar Documents

Publication Publication Date Title
CA2376202A1 (en) Novel preparation and administration form comprising an acid-labile active compound
MY138975A (en) Novel preparation and administration form comprising an acid-labile active compound
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
IL101225A0 (en) Bi-and tricyclic amino alcohol esters,their preparation and pharmaceutical compositions containing them
GB2062465B (en) Topical preparation containing nitroglycerine and optionally other medicaments
MY111841A (en) Injectable liposomal pharmaceutical preparations
IE940583L (en) Topical antimicrobial pharmaceutical compositions
ATE427925T1 (en) PHENOXYCARBONIC ACID COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
GR890100467A (en) METHOD FOR THE MANUFACTURE OF INTERESTING PHARMACEUTICAL COMPOSITION.
SG148028A1 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
ATE84045T1 (en) INHIBITING SUBSTANCES ENKEPHALINASE-B THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS.
MY143793A (en) Non-tabletted, chewable, individually dosed administration forms
CA2313878A1 (en) Composition for suppressing behavior problems of pets
DE60027601D1 (en) DRUG PREPARATION WITH CONTROLLED RELEASE CONTAINING TRAMADOL HYDROCHLORIDE
ES2021904A6 (en) Piperazinecarboxylic acid, its preparation and pharmaceutical compositions containing it
EP0793963A4 (en) PREPARABLE TRANSDERMAL PREPARATION
HUT39752A (en) Insecticide, acaricide, and nematocide compositions containing pyridyl-thiono-phosphoric acid esters as active ingredients and process for preparing the active ingredient
EP0239527A3 (en) Composition adopted for use as a transdermal formulation
PE59499A1 (en) PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE
ES2168351T3 (en) PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND PROCEDURE FOR PREPARATION.
MY142110A (en) Matrix for sustained, invariant and independent release of active compounds
CA2017155A1 (en) Method for transplantation of fertilized ova
EP1046337A3 (en) Waterbased formulations having fungicidal activity